Vesugen: Risks & Legal Status
Important safety information, risks, and regulatory status
Important Safety Warnings
- Evidence-gap risk: No randomised trials, no PubMed-indexed human pharmacokinetic data, no structured safety registry. The only PubMed-anchored dose is from a mouse Alzheimer's model (PMID 34071923), not a human cardiovascular study.
Mitigation: Do not self-administer outside structured research. Consult a clinician for any cardiovascular concerns.
📌TL;DR
- •5 risk categories identified
- •1 high-severity risks
- •Legal status varies by country (5 countries listed)
Risk Assessment
No randomised trials, no PubMed-indexed human pharmacokinetic data, no structured safety registry. The only PubMed-anchored dose is from a mouse Alzheimer's model (PMID 34071923), not a human cardiovascular study.
Mitigation: Do not self-administer outside structured research. Consult a clinician for any cardiovascular concerns.
Material sold online as Vesugen is research-chemical grade. No manufacturer with FDA-recognised cGMP status produces Vesugen. Purity, identity, and absence of contaminants are not guaranteed.
Mitigation: If proceeding despite the gaps, prefer vendors that publish third-party HPLC and mass-spectrometry certificates of analysis for each lot.
Personal importation and possession of research peptides occupies a grey zone in most Western jurisdictions. FDA, MHRA, and Health Canada have escalated enforcement against research-chemical peptide vendors.
Mitigation: Verify current local regulations before purchase or import.
The Khavinson 2021 docking predictions identify KED binding to promoters of CASP3, APOE, SOD2, PPARG and other genes implicated in cancer biology. Long-term effects of modulating these promoters have not been studied for Vesugen specifically.
Mitigation: Avoid in anyone with active malignancy, strong family cancer history, or known precancerous lesions until carcinogenicity data are available.
The only PubMed-anchored Vesugen dose is the 5xFAD mouse dose of 400 mcg/kg/day intraperitoneal injection. Community subcutaneous dosing of 1-2 mg per injection exceeds simple allometric extrapolation by a substantial multiple.
Mitigation: Recognise that community doses are not anchored to the only PubMed-indexed dose-response data.
Risk assessment matrix for Vesugen
Infographic pending generation
⚠️Important Warnings
- •Vesugen is not FDA-, EMA-, MHRA-, or Health Canada-approved for any indication
- •Do not use Vesugen as a substitute for evidence-based cardiovascular prevention
- •Do not use Vesugen in anyone with active malignancy or known precancerous lesions
- •Mouse-to-human dose translation is uncertain; community doses are not anchored to clinical data
- •Verify peptide identity via certificate of analysis if proceeding
- •Avoid in pregnancy, breastfeeding, and pediatric populations
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Unregulated | Not FDA-approved. Not a controlled substance. Sold only as a research chemical. |
| European Union | Unregulated | Not EMA-approved. Not a controlled substance. Research-chemical classification. |
| United Kingdom | Unregulated | Not MHRA-approved. Not a controlled substance. Research-chemical classification. |
| Canada | Unregulated | Not Health Canada-approved. Not a controlled substance. Research-only. |
| Russia | Unregulated | Used in Russian bioregulation clinic practice under the Khavinson framework. Not a standard registered pharmaceutical product. |
Legal status map for Vesugen
Infographic pending generation
Vesugen (KED, T-38) Risks and Legal Status#
Vesugen sits at the intersection of weak evidence, unregulated sourcing, and theoretical gene-expression concerns. None of these alone is a definitive show-stopper -- but in combination they make Vesugen a higher-risk choice than evidence-based cardiovascular prevention. Last verified June 4, 2026.
Categories of Risk#
Evidence-Gap Risk (High)#
There are no randomised trials, no PubMed-indexed human pharmacokinetic data, no validated dose-response curve, and no structured safety registry for Vesugen. The only PubMed-anchored dose is the 5xFAD mouse dose of 400 mcg/kg/day intraperitoneal injection (PMID 34071923)1 -- which is a neurological endpoint in a mouse model, not a vascular endpoint in humans.
Sourcing and Product-Quality Risk (Medium)#
Material sold as Vesugen is produced in research-chemical-grade facilities, not under FDA-recognised cGMP. Purity, identity, and contaminant profile depend entirely on the manufacturer. Independent third-party testing is not standardised across vendors.
Regulatory Enforcement Risk (Medium)#
The research-chemical peptide market has faced rising regulatory pressure. The FDA has issued warning letters to peptide vendors and added several peptides to its "Bulks List" exclusion in recent years. Personal importation of Vesugen may face border-services intervention in some jurisdictions.
Theoretical Carcinogenicity / Gene-Expression Risk (Medium)#
The Khavinson 2021 in-silico docking predictions identify KED binding to promoters of CASP3, APOE, SOD2, PPARG and other genes implicated in cancer biology1. Long-term effects of modulating these promoters have not been studied for Vesugen specifically. The reasonable precaution is to avoid use in anyone with active malignancy, known precancerous lesions, or strong family cancer history.
Mouse-to-Human Dose Translation Risk (Medium)#
The 5xFAD mouse dose of 400 mcg/kg/day extrapolates allometrically (via body-surface-area scaling) to roughly 32-35 mcg/kg/day in humans -- about 2.2-2.5 mg/day for a 70 kg adult. Community subcutaneous dosing of 1-2 mg per injection (often daily) is in the same magnitude range or higher, and is not anchored to a human PK or PD study.
Theoretical Anticoagulant Interaction Risk#
If the proposed Vesugen vascular-endothelial effects (SIRT1 induction, endothelial function modulation) are operative, theoretical interactions with anticoagulants (warfarin, DOACs) and antiplatelet agents (aspirin, clopidogrel) cannot be excluded. No interaction data exist.
What an Informed-Risk Posture Looks Like#
For anyone choosing to use Vesugen despite the gaps:
- Discuss with a clinician before starting, particularly if cardiovascular concerns motivate the choice
- Obtain baseline cardiovascular evaluation -- blood pressure, lipid panel, basic ECG if relevant
- Verify product identity via vendor-provided certificate of analysis (HPLC + mass spec confirming KED sequence)
- Prefer single-peptide use over multi-peptide stacks to localise any adverse event
- Stop and seek care immediately for unexpected symptoms (chest pain, palpitations, unusual bleeding, allergic-type reaction)
- Keep a symptom and dose diary -- the only structured information available
Bottom Line#
The Vesugen risk profile is dominated by data absence rather than identified harm. That distinction matters: absence of evidence is not evidence of safety. Until independent replication, human pharmacokinetic data, and at least one registered trial for a vascular endpoint are available, Vesugen should be treated as an investigational compound with an undefined risk profile.
References#
Related Reading#
- Vesugen research and evidence base
- Vesugen dosing protocols
- Vesugen side-effects profile
- Prostamax risks
- Pinealon risks
Footnotes#
-
Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M. Neuroprotective Effects of Tripeptides -- Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals. 2021. PMID: 34071923. DOI: 10.3390/ph14060515. ↩ ↩2
Frequently Asked Questions About Vesugen
Is Vesugen legal to buy in the United States?
Vesugen is not FDA-approved and is not a controlled substance. It is sold as a research chemical, which occupies a legal grey zone -- generally not actionable for personal possession but subject to escalating FDA enforcement against vendors. Status can change.
Has the FDA taken action against Vesugen specifically?
No FDA enforcement action specifically naming Vesugen is identified. The FDA has issued multiple warning letters to peptide vendors more generally, and the broader regulatory environment for research-chemical peptides has tightened.
Is Vesugen legal in Canada?
Vesugen is not Health Canada-approved and is not licensed for sale as a natural health product or pharmaceutical. Personal-use importation faces border-services risk.
What are the biggest non-efficacy risks?
The biggest risks beyond unproven efficacy are: (1) gene-expression- modulating mechanism with no long-term safety data; (2) research- chemical sourcing with no guaranteed purity or identity; (3) potential drug interactions with anticoagulants and SIRT1-targeting interventions; (4) mouse-to-human dose translation uncertainty (community doses exceed allometric extrapolation from the only PubMed-indexed dose).
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.